LEX 032

08/01/1999 - "Because of its considerable amelioration of microcirculatory perfusion, Lex032 might be useful in the treatment of pancreatic I/R tissue damage (e.g., cardiac bypass surgery, pancreas transplantation, and hemorrhagic shock) by prevention of capillary perfusion failure."

05/01/2002 - "Focal cerebral ischemia in the rat was produced by intravascular occlusion of the middle cerebral artery for a period of 30 min. Just prior to thread withdrawal (i.e., reperfusion), rats received an iv bolus administration of either vehicle or LEX032 (50 mg/kg), an optimal dose chosen based on previous studies. "

11/01/1999 - "Therefore, LEX 032 is expected to prevent or minimise neutrophil mediated reperfusion injury. "
11/01/1999 - "LEX 032: a novel recombinant human protein for the treatment of ischaemic reperfusion injury."
05/01/2002 - "This data demonstrates that LEX032 reduces brain injury and suggests that serine protease inhibitors may reduce ischemia/reperfusion injury by decreasing leukocyte activation and migration."
11/01/1999 - "Since LEX 032 has been shown to limit neutrophil mediated reperfusion damage, it may find use either alone, to ameliorate damage occurring spontaneously during ischaemic stroke, or in combination therapy with tPA to reduce reperfusion injury secondary to thrombolytic therapy. "
05/01/1997 - "LEX 032, a genetically engineered recombinant human nonglycosylated serpin, has been shown to have antiinflammatory properties in a number of animal models of inflammation and reperfusion injury. "

05/01/2002 - "On a scale ranging from 0 to 3, with three indicating the most severely injured, the LEX032 animals had a significantly better neurologic score (1.0 +/- 0.9) than the untreated animals (2.3 +/- 0.5) 24 h after ischemia. "
05/01/2002 - "LEX032, a novel recombinant serpin, protects the brain after transient focal ischemia."
08/01/1999 - "Twenty-eight anesthetized rats received either Lex032 or NaCl 0.9% as a control solution during baseline conditions or after 1 h of complete reversible ischemia induced by microclip occlusion of the pancreatic arteries. "
05/01/2002 - "This investigation examined the effectiveness of a serine protease inhibitor (LEX032) when used as a cerebral protective agent after ischemia. "
08/01/1999 - "Inhibition of neutrophil proteinases by recombinant serpin Lex032 reduces capillary no-reflow in ischemia/reperfusion-induced acute pancreatitis."

10/01/1995 - "Moreover, administration of LEX032 significantly preserved superior mesenteric artery (SMA) endothelial function as measured by the relaxation response of isolated (SMA) rings to acetylcholine, an endothelium-dependent vasodilator (64 +/- 10% vs. 25 +/- 6%, p < .01 compared with untreated trauma rats). "